Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

696.79 +1.80 (+0.26%)
Streaming Delayed Price Updated: 1:36 PM EST, Nov 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2
...
24 25 26 27 28 29 30 31 32
...
57 58 Next >
News headline image
Dupixent® (dupilumab) Significantly Reduced COPD Exacerbations in Second Positive Phase 3 Trial, Accelerating FDA Submission and Confirming Potential to Become First Approved Biologic for This Serious Disease
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
If You Invested $100 In This Stock 5 Years Ago, You Would Have $200 Today ↗
 
Via Benzinga
News headline image
9 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
How Is The Market Feeling About Regeneron Pharmaceuticals? ↗
 
Via Benzinga
News headline image
Regeneron Announces Investor Conference Presentation
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Where Regeneron Pharmaceuticals Stands With Analysts ↗
 
Via Benzinga
News headline image
2 Soaring Stocks to Buy and Hold ↗
Both of these companies crushed earnings season. 
Via The Motley Fool
News headline image
Regeneron Commits $34 Million Over Five Years to Continue to Sponsor the Regeneron International Science and Engineering Fair (ISEF)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
7 Underappreciated Biotech Stocks to Pick Up on the Cheap ↗
With questions rising about the economy, investors may consider undervalued biotech stocks for their relative insulation factor. 
Via InvestorPlace
Topics Economy
News headline image
3 Biotech Stocks That Are Betting on the Future of Gene Editing ↗
These three companies have gene editing therapies in late-stage clinical trials, making them promising biotech stocks to buy right now. 
Via InvestorPlace
News headline image
Celldex Makes A Bullish Move As It Looks To Take On Regeneron, Sanofi ↗
The company is looking to take on Regeneron and Sanofi's Dupixent in skin diseases. 
Via Investor's Business Daily
News headline image
Why Is Eye Disease-Focused Adverum Bio Stock Trading Higher Today? ↗
Adverum Biotechnologies Inc (NASDAQ: ADVM) revealed updated data from the OPTIC extension study of ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022) in patients with wet AMD during... 
Via Benzinga
News headline image
Regeneron Edges Higher On Third-Quarter Beat As High-Dose Eylea Delivers ↗
The launch of high-dose Eylea is off to a strong start in the U.S. 
Via Investor's Business Daily
News headline image
Regeneron Pharmaceuticals Unusual Options Activity ↗
 
Via Benzinga
News headline image
Regeneron Pharmaceuticals Stock Upgraded After Q3, But There Is A Headwind - Analyst Review ↗
Thursday, Regeneron Pharmaceuticals Inc (NASDAQ: REGN) reported better-than- 
Via Benzinga
News headline image
Stock Market Rally Back In Force As Treasury Yields Plunge; Arista, Palantir Among Winners: Weekly Review ↗
Bulls are back in control as the major indexes confirmed the uptrend this week. 
Via Investor's Business Daily
News headline image
Regeneron to Highlight Scientific Advancements Across Diversified Pipeline in Difficult-to-Treat Blood Cancers and Disorders at ASH
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
$100 Invested In Regeneron Pharmaceuticals 15 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
Apple, AMD, Palantir Earnings On Deck This Week As Market Seeks Positive Catalysts In Fed Decision Week ↗
S&P 500 earnings is expected to grow in Q3, reversing a four-quarter slide, as the reporting season enters its third week. 
Via Benzinga
Topics Economy Stocks
News headline image
Regeneron's Skin Drugs Propel Revenue In Q3, Witnesses Strong Demand For Higher Dose Version Of Flagship Eye Drug ↗
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) earned Q3 adjusted EPS of $11.59, up 4% Y/Y, beating the $10.77 Street estimate 
Via Benzinga
News headline image
US Stocks On Track For Solid Start Amid Lingering Fed Optimism: Traders Eye Earnings From Market Bellwether Apple ↗
After the Federal Reserve‘s decision, the stock market rally is poised to gain momentum on Thursday, with stock futures indicating an uptick. 
Via Benzinga
Topics Economy
News headline image
1 Supercharged Growth Stock That Could Make You a Millionaire in 10 Years ↗
Biotech may be in a slump, but this innovator holds enormous promise as a potential wealth escalator. 
Via The Motley Fool
News headline image
Regeneron Reports Third Quarter 2023 Financial and Operating Results
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
EYLEA® HD (aflibercept) Injection 8 mg Data Presentations at AAO Reinforce Efficacy and Safety Profile in Wet Age-related Macular Degeneration and Diabetic Macular Edema
Long-term data and subgroup analyses from pivotal EYLEA HD clinical program highlight durability of visual improvements and consistent safety across extended dosing intervals and patient... 
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Healthcare Playbook: Hardly Defensive With A Covid Hangover In Biotech ↗
Market Bubbles may take a long time to clear and we created a big one in July 2021 dealing with the COVID pandemic. 
Via Talk Markets
News headline image
Earnings Scheduled For November 2, 2023 ↗
Companies Reporting Before The Bell • AudioCodes (NASDAQ:AUDC) is estimated to report quarterly earnings at $0.18 per share on revenue of $61.52 million. 
Via Benzinga
News headline image
MAIA Biotechnology Reports Positive Phase 2 Clinical Trial Data On Its Treatment For Non-Small Cell Lung Cancer ↗
New results from a targeted therapy and immuno-oncology company show the promising potential efficacy of one of its first-in-class treatments.  
Via Benzinga
News headline image
Gene Therapy Could Be On the Cusp of a Major Breakthrough, but Investors May Have to Remain Patient ↗
This gene-editing pioneer could make history this week. But shareholders should remain focused on the long term. 
Via The Motley Fool
News headline image
Are Your Eyes At Grave Risk? FDA Issues Dangerous Warning Over Popular Drops From CVS, Target, Cardinal Health And More ↗
The U.S. 
Via Benzinga
News headline image
SNY Stock Sinks 15% as Sanofi Plans Consumer Unit Spinoff ↗
The happy talk in Sanofi's press release didn't help with analysts, who have been disappointed in the company and SNY stock all year. 
Via InvestorPlace
< Previous 1 2
...
24 25 26 27 28 29 30 31 32
...
57 58 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.